

Drug Utilization Review Board
(DUR Board)
Meeting – February 10, 2010 @ 6:00 p.m.

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. January 13, 2010 DUR Minutes – Vote

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for September 2009
 - B. Medication Coverage Activity Audit for January 2010
 - C. Help Desk Activity Audit for January 2010

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

- 5. Action Item – Vote to Prior Authorize Antipsychotics – See Appendix C.**
 - A. COP Recommendations
 - B. Second Opinion Process
 - C. Continuous Use Questionnaire Process

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

- 6. Action Item – Vote to Prior Authorize Zipsor™, Cambia™, and to Update NSAID PBPA Criteria and 30 Day Notice to Prior Authorize Pennsaid® – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Ribavirin Capsules, Solution, and Dose Packs – See Appendix E.**
 - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

8. **30 Day Notice to Prior Authorize Twynsta[®] – See Appendix F.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

9. **FDA and DEA Updates – See Appendix G.**

10. **Future Business**
 - A. Anxiolytic Criteria Review
 - B. Annual Review of Smoking Cessation Products
 - C. Annual Review of HFA Products
 - D. Annual Review of Growth Hormones
 - E. New Product Reviews

11. **Adjournment**